ImmunoGen Presents Full Results From Positive SORAYA Trial Of Mirvetuximab In Ovarian Cancer

ImmunoGen Inc. (IMGN) announced full results from the pivotal SORAYA trial evaluating the efficacy and safety of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRa)-high platinum-resistant ovarian cancer who have been previously treated with Avastin or bevacizumab.

The trial met primary endpoint with confirmed objective response rate of 32.4%, including 5 complete responses; updated median duration of response of 6.9 months.

The company noted that Mirvetuximab demonstrated meaningful anti-tumor activity, consistent safety, and favorable tolerability in fra-high platinum-resistant ovarian cancer.

The company expects to submit Biologics License Application in this month.

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT